Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.
Zacharias NM, Rupe ES, Chen X, Kotecha RR, Rieke DT, McGregor BA, Pesquera P, Yu Z, Grover A, Daw NC, Wang E, Chan SWS, Douglas-Lindsay D, Fan AC, Knoche EM, Kyriakopoulos CE, Lalani AA, Mantia CM, Merla A, Voss MH, Pfanzelter N, Ramakrishna S, Reaume NM, Tang T, Ingram DR, Shamsutdinova D, Wani KM, Wang WL, Lazar AJ, Sheth RA, Rao P, Grimm SL, Coarfa C, He R, Qian J, Duan F, Bisht D, Chauhan PK, Perelli L, Genovese G, Yang L, Lin C, Karam JA, La Posta L, Dondossola E, Basar R, Uprety N, Rezvani K, Gao J, Wang L, Solis Soto LM, Lim B, Tannir NM, Karki M, Msaouel P.
Zacharias NM, et al. Among authors: merla a.
Clin Cancer Res. 2026 Aug 21. doi: 10.1158/1078-0432.CCR-26-0392. Online ahead of print.
Clin Cancer Res. 2026.
PMID: 42627757